cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23731095
title: Supplementary Material for: Genetic factors in familial manifestation of primary mediastinal large B-cell lymphoma over two generations

description: Introduction: Primary mediastinal large B-cell lymphoma (PMBL) is a rarely occurring lymphoid malignancy, which typically affects young adults and presents itself as an anterior mediastinal mass. Gene expression profiling, as well as somatic genetic analysis revealed that it is closely related to classical Hodgkin lymphoma, whereas morphologically it tends to resemble diffuse large B-cell lymphoma. Familial clustering of PMBL is rare - only two reports have been published to date. While generally accepted that positive family history is associated with increased risk of developing a lymphoma, genetic risk factors, which might predispose to PMBL are largely unknown. Case presentation: We performed germline and tumor genetic analysis by whole exome sequencing and array-CGH of a family, in which the father and the son both developed a PMBL. Germline investigations of both affected patients and of their two unaffected family members has not been able to provide a single risk factor associated with lymphoma predisposition. In addition, genes that were previously implicated in increased risk for PMBL, namely MLL (KMT2A) and TIRAP, were found to be intact in all investigated family members. Somatic genetic investigations identified known as well as novel genetic aberrations in tumors of affected subjects. Discussion/Conclusion: We conclude that predisposition to a PMBL might be inherited through a combination of low- or moderate-risk factors and provide a shortlist of most likely selected candidates, which can be used in future studies.
DOI: 10.6084/m9.figshare.23731095.v1
title: Supplementary Material for: Genetic factors in familial manifestation of primary mediastinal large B-cell lymphoma over two generations

description: Introduction: Primary mediastinal large B-cell lymphoma (PMBL) is a rarely occurring lymphoid malignancy, which typically affects young adults and presents itself as an anterior mediastinal mass. Gene expression profiling, as well as somatic genetic analysis revealed that it is closely related to classical Hodgkin lymphoma, whereas morphologically it tends to resemble diffuse large B-cell lymphoma. Familial clustering of PMBL is rare - only two reports have been published to date. While generally accepted that positive family history is associated with increased risk of developing a lymphoma, genetic risk factors, which might predispose to PMBL are largely unknown. Case presentation: We performed germline and tumor genetic analysis by whole exome sequencing and array-CGH of a family, in which the father and the son both developed a PMBL. Germline investigations of both affected patients and of their two unaffected family members has not been able to provide a single risk factor associated with lymphoma predisposition. In addition, genes that were previously implicated in increased risk for PMBL, namely MLL (KMT2A) and TIRAP, were found to be intact in all investigated family members. Somatic genetic investigations identified known as well as novel genetic aberrations in tumors of affected subjects. Discussion/Conclusion: We conclude that predisposition to a PMBL might be inherited through a combination of low- or moderate-risk factors and provide a shortlist of most likely selected candidates, which can be used in future studies.
DOI: 10.6084/m9.figshare.23731098
title: Supplementary Material for: Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements.

description: Introduction: A variety of gene rearrangements and molecular alterations are key drivers in the pathobiology of acute leukemia and myeloid disorders; current classification systems increasingly incorporate these findings in diagnostic algorithms. Therefore, clinical laboratories require versatile tools, which can detect an increasing number and variety of molecular and cytogenetic alterations of clinical significance. Methods: We validated an RNA-based NGS assay that enables the detection of: i) numerous hybrid fusion transcripts (including rare/novel gene partners), ii) aberrantly expressed EVI1(MECOM) and IKZF1 (Del Exons 4-7) transcripts, and iii) hotspot variants in KIT, ABL1, NPM1 (relevant in the context of gene rearrangement status). Results: For hybrid fusion transcripts, the assay showed 98-100% concordance for known positive and negative samples, with an analytical sensitivity (ie, limit of detection) of approximately 0.8% cells. Cases with underlying EVI1 (MECOM) translocations demonstrated increased EVI1(MECOM) expression. Aberrant IKZF1 (Del Exons 4-7) transcripts detectable with the assay were also present on orthogonal RT-PCR. Specific hotspot mutations in KIT, ABL1 and NPM1 detected with the assay showed 100% concordance with orthogonal testing. Lastly, several illustrative cases are included to highlight the assay’s clinically relevant contributions to patient work-up. Discussion/Conclusion: Through its ability to simultaneously detect various gene rearrangements, aberrantly expressed transcripts and hotspot mutations, this RNA-based NGS assay is a valuable tool for clinical laboratories to supplement other molecular and cytogenetic methods used in the diagnostic workup, and in clinical research, for patients with acute leukemia and myeloid disorders.
DOI: 10.6084/m9.figshare.23731119
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23731122
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23731122.v1
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23731125
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.6084/m9.figshare.23731125.v1
title: Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

description: Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-checkpoint inhibitors(ICI)+tyrosine-kinase inhibitors(TKIs) are lacking. Objectives: This network meta-analysis(NMA) aims to indirectly compare the efficacy and the safety of first-line systemic therapies for unresectable-advanced HCC. Method:A literature search of MEDLINE, EMBASE and SCOPUS databases was conducted up to 31st October, 2022. Phase III randomized controlled trials(RCTs) testing TKIs, including Sorafenib and Lenvatinib, or ICIs reporting overall survival(OS) and progression-free survival(PFS) were included. Individual survival data were extracted from OS and PFS curves to calculate restricted mean survival time (RMST). A Bayesian NMA was performed to compare treatments in terms of efficacy(15- and 30-month OS, 6-month PFS) and safety, represented by grade≥3(severe)adverse events(SAEs). The incremental safety-effectiveness ratio(ISER) as measure of net health benefit was calculated as the difference in SAEs probability divided by survival difference between the 2 most effective treatments. Results:Nine RCTs enrolling 6600 patients were included. Atezolizumab plus bevacizumab showed the highest probability(88%)of achieving the 30-month OS landmark. Lenvatinib showed a probability of 86% of achieving best PFS outcomes. ICI monotherapies ranked as most tolerable. Atezolizumab plus Bevacizumab showed the best net health benefit for OS, compared to Durvalumab plus Tremelimumab. When evaluating the net health benefit for PFS, at a willingness-to-risk threshold of 10% of SAEs for life-month gained, Atezolizumab plus Bevacizumab was favored in 78% of cases, while at threshold of 30% of SAEs for life-month gained, Lenvatinib was favored in 76% of cases. Conclusions: Atezolizumab plus Bevacizumab is the best treatment in terms of net benefit and therefore it should be recommended as standard of care. Compared to Atezolizumab plus Bevacizumab, Lenvatinib monotherapy had the best net benefit for PFS when physicians and patients are available to accept a higher risk of toxicity.
DOI: 10.34944/dspace/8820
title: School-based Assaultive Violence Prevention in Middle and High Schools Scoping Review Search Strategy

description: A summary of the search results from databases: APA PsycINFO (EBSCOhost): 1,216 results; PubMed (NLM): 1,227 results; ERIC (EBSCOhost): 1,574 results; NCJRS Abstracts (ProQuest): 1,214 results; Applied Social Sciences Index & Abstracts (ProQuest): 310 results; Web of Science Core Collection (Clarivate Analytics): 665 results. The search resulted in 6,616 studies and 1,485 duplicate studies were found and omitted by the librarian (OGC) using the EndNote 20. This resulted in 5,100 records to screen from databases and 41 to screen from other methods, resulting in a total of 5,141 records. Studies were screened by title and abstract by two blinded and independent reviewers. If a tiebreaker was needed, a third reviewer was used. This process was repeated for full text screening and data selection.
description: Search Methods for Identification of Studies: To identify studies to include or consider for this scoping review, the review team worked with a research librarian (OGC) to develop detailed search strategies for each database. The PRISMA-S extension was followed for search reporting. The research librarian (OGC) developed the search for APA PsycINFO (EBSCOhost) and translated the search for every database searched. The APA PsycINFO (EBSCOhost) search strategy was reviewed by the research team to check for accuracy and term relevancy, and all searches were peer-reviewed by another research librarian (AGS) following the PRESS checklist. The databases included in this search are PubMed (NLM), Education Resources Information Center (ERIC; EBSCOhost), National Criminal Justice Reference Service Abstracts (NCJRS; ProQuest), Applied Social Sciences Index & Abstracts (ASSIA; ProQuest), and Web of Science Core Collection (Clarivate Analytics), which were searched using a combination of keywords and subject headings. A grey literature search included ProQuest Dissertations & Theses Global (PQDT), Policy File Index (ProQuest), Rutgers University Don M. Gottfredson Library of Criminal Justice Gray Literature Database, Policy Commons, and TRIP Pro. All final searches were performed on May 15, 2023. The full search strategies as reported by the librarian are provided.
DOI: 10.34808/wc10-3980
title: Selection of material for infiltration of non-stoichiometric Sr0.95Ti0.3Fe0.7O3-δ

description: The porous electrodes used for the infiltration were prepared from A-site non-stoichiometric Sr0.95Ti0.3Fe0.7O3-δ synthesized by the conventional solid state reaction method. Screen printed electrodes (0.5 cm2) on CGO-20 substrate, were fired at 800 °C for 2 hours in an air atmosphere. Infiltration of the scaffolds was performed by a water-based precursor solution of (La0.6Sr0.4)0.98CoO3 (LSC) and Ce0.8Gd0.2O1.9 (CGO). A mixture of water and ethanol (9:1 by vol.) with dissolved nitrates of La, Sr, and Co (Sigma Aldrich, &gt;99%) and Pluronic P123 (Sigma Aldrich, Mn ~5800) surfactant was used. The prepared precursor solution was ~0.6 M with ~0.1 g of P123 per 100 ml. After the infiltration step, the samples were dried at 80 °C and heated in a furnace up to 350 °C for 10 mins. The process was repeated until a total of 10% weight gain was obtained for the electrodes on both sides. At the end, the samples were heated up to 600 °C.
Symmetrical electrode cells were tested in a 4-wire compression cell using electrochemical impedance spectroscopy (EIS) using a Novocontrol Alpha-A with a ZG-4 interface. The measurements were carried out at an amplitude of 25 mV in the frequency range from 3 MHz to 0.05 Hz in synthetic air (AirLiquide, 4N). Symmetrical samples were tested by in situ cyclic heating up to 600 °C ÷ 800 °C and cooling down progressively to 400 °C.
Presented in this dataset results are obtained at 700 °C after cooling from 750 °C. This dataset also contains the results of the DRT analysis of the presented EIS results.
As can be seen, infiltration of the STF-x electrode with a mixed ionic and electronic conductive material significantly improves the results, while infiltration with a material with pure ionic conductivity worsens the results.
DOI: 10.6084/m9.figshare.22261912.v9
title: 博士论文补充材料

description: Supplementary Dataset, MAGs (with locus_tag) and meta-transcripts
DOI: 10.5281/zenodo.8026174
title: Single cell analysis of human mesenchymal stem cells

description: This dataset including the RDS files, including meta data, labeled assays, and reduction map information in order to ensure the reproducibility of the scRNA-seq data of human MSCs. The research "Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1" has been published on Nature Communications (https://doi.org/10.1038/s41467-023-39958-5).
DOI: 10.5281/zenodo.8026173
title: Single cell analysis of human mesenchymal stem cells

description: This dataset including the RDS files, including meta data, labeled assays, and reduction map information in order to ensure the reproducibility of the scRNA-seq data of human MSCs. The research "Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1" has been published on Nature Communications (https://doi.org/10.1038/s41467-023-39958-5).
DOI: 10.6084/m9.figshare.23635173.v1
title: Tooth wear in diabetic population

description: data represents tooth wear-attrition, erosion and abrasion in diabetic patients and its impact on quality of life.